To determine whether TRAIL and VEN alone or in combination are effective against AML cells expressing TP53INP2 in vivo, a PDX mouse model was generated by injecting mice with leukemic cells from AML patient #3 carrying NPM1-mA. Here, TP53INP2 is linked to acute myeloid leukemia.